Sugi Predict

Sugi Predict / Compounds / SCHEMBL6602091

SCHEMBL6602091

SCHEMBL6602091

COC(=O)c1cccnn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.56
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.47
▸ AHR P35869 1/20 0.45
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRG2 P18507 1/20 0.41
▸ GABRB3 P28472 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27539765 0.98 P2RX7 (0.55) P2RX7KMT2AMEN1ALDH1A1AHR
Hydrochloric Acid SCHEMBL29205819 0.98 P2RX7 (0.55) P2RX7KMT2AMEN1ALDH1A1AHR
SCHEMBL5026814 0.83 P2RX7 (0.55) P2RX7KMT2AMEN1ALDH1A1AHR
SCHEMBL27708372 0.81 P2RX7 (0.49) P2RX7KMT2AMEN1ALDH1A1AHR
SCHEMBL28418161 0.80 P2RX7 (0.52) P2RX7KMT2AMEN1AHRL3MBTL1
SCHEMBL28818671 0.80 P2RX7 (0.56) P2RX7KMT2AMEN1AHRL3MBTL1
SCHEMBL1479818 0.80 P2RX7 (0.52) P2RX7KMT2AMEN1ALDH1A1AHR
SCHEMBL30079550 0.79 ALDH1A1 (0.48) P2RX7KMT2AMEN1ALDH1A1AHR
SCHEMBL30187763 0.79 ALDH1A1 (0.48) P2RX7KMT2AMEN1ALDH1A1AHR
SCHEMBL2930179 0.79 CYP1A2 (0.62) P2RX7ALDH1A1MAPK1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 — — US claimed
CN-104284896-B Substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-06-01 — — CN claimed
CN-104284896-A Substituted imidazopyridazines BAYER IP GMBH 2015-01-14 — — CN claimed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
EP-4633734-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING Wavebreak Therapeutics, LLC (US) 2025-10-22 — — EP disclosed
CN-120040441-A Compositions and methods for treating cancer A2A制药有限公司 2025-05-27 — — CN disclosed
WO-2025045233-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)股份有限公司 2025-03-06 — — WO disclosed
CN-119522217-A Compositions and methods for treating cancer A2A制药有限公司 2025-02-25 — — CN disclosed
US-20240368122-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2024-11-07 — — US disclosed
EP-4426705-A1 CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR F. Hoffmann-La Roche AG (CH) 2024-09-11 — — EP disclosed
CN-101508676-A Synthesis process of 6-methoxy pyridazine-3- carboxylic acid WUHAN INST TECHNOLOGY (CN) 2009-08-19 — — CN disclosed
CN-101083994-A Heterocyclic derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2007-12-05 — — CN disclosed
CN-1155600-C 2, 3-diaryl pyrazolo [1, 5-b ] pyridazine derivatives, their preparation and their use as cyclooxygenase 2 inhibitors — 2004-06-30 — — CN disclosed
EP-1102757-B1 SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS GLAXO GROUP LTD (GB) 2004-04-14 — — EP disclosed
US-6498174-B1 AGONISTS TO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; MODULATING BLOOD GLUCOSE AND LIPID LEVELS; REDUCING DYSLIPIDEMIA AND HYPERINSULINEMIA ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROME SMITHKLINE BEECHAM CORPORATION 2002-12-24 — — US disclosed
EP-1102757-A1 SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS GLAXO GROUP LIMITED (GB) 2001-05-30 — — EP disclosed
CN-1278263-A 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors GLAXO GROUP LTD (GB) 2000-12-27 — — CN disclosed
WO-2000008002-A1 SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS GLAXO GROUP LIMITED (GB) 2000-02-17 — — WO disclosed
US-5059599-A Anxiolytic agents PIERRE FABRE MEDICAMENT (FR) 1991-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 P2RX7 3982/4885KMT2A 289/4885MEN1 4533/4885
US-20240368122-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF JAK2, JAK1, JAK3 P2RX7 3251/4885KMT2A 783/4885MEN1 3908/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 P2RX7 1935/4885KMT2A 605/4885MEN1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.